Biovica participates at ASCO, June 3-7, Chicago

Biovica will attend the ASCO Annual Meeting, an event that brings together 30 000 oncology professionals from around the world. Biovica aims to expand the collaboration and research network and to share the latest insights from on going clinical trials. “At ASCO we look forward to meet our academic partners and to expand [...]

2017-01-03T10:45:48+00:00 May 31st, 2016 08:30|News|

Biovica acquires cSens – creating opportunities for solving cancer diagnostic challenges

Biovica has acquired cSens AB, a company that has developed a PCR-based platform for the analysis of serum thymidine kinase (TK) enzyme activity, which correspond to tumor proliferation and cancer aggressiveness. The cSens technology complements Biovica’s current TK assay DiviTum ™, which is currently included in clinical studies with leading cancer institutes throughout the world. [...]

2017-01-03T10:46:09+00:00 May 17th, 2016 08:30|Regulatory|

Maria Holmlund elected new member of Biovica board of directors

Maria Holmlund was elected as a new member of the Biovica board of directors at an extra shareholders meeting held on March 30, 2016. Maria has 30 years of experience in the life science and diagnostic industry and she has previously held senior management positions as CEO, business area manager and marketing manager at [...]

2017-01-03T10:47:40+00:00 May 4th, 2016 14:00|Regulatory|